Share Price and Basic Stock Data
Last Updated: January 23, 2026, 9:37 pm
| PEG Ratio | 2.25 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vimta Labs Ltd operates in the medical research services industry, reporting a market capitalization of ₹2,288 Cr and a current share price of ₹514. The company’s revenue from operations has shown a positive trajectory, increasing from ₹276 Cr in FY 2022 to ₹315 Cr in FY 2023, and further to ₹344 Cr in FY 2025. The trailing twelve months (TTM) revenue stands at ₹384 Cr. Quarterly sales have fluctuated, with the most recent quarter (Sep 2023) reporting ₹64 Cr, down from ₹82 Cr in Jun 2023. However, the company is poised for recovery, with projected sales of ₹85 Cr in Sep 2024 and ₹90 Cr in Dec 2024. This pattern illustrates a cyclical nature to revenue generation, which is common in this sector, influenced by project timelines and client demands. The overall sales growth demonstrates Vimta’s resilience and adaptability within a competitive landscape.
Profitability and Efficiency Metrics
Vimta Labs has maintained a commendable operating profit margin (OPM) of 34%, indicating effective cost management relative to its revenues. The company’s net profit for FY 2023 was ₹47 Cr, which rose to ₹67 Cr in FY 2025, reflecting a robust net profit margin of 12.88% in the latest fiscal year. The interest coverage ratio stood at an impressive 42.79x, highlighting Vimta’s strong ability to meet its interest obligations effortlessly. Additionally, return on equity (ROE) was recorded at 19.4%, suggesting efficient utilization of shareholders’ funds to generate profits. However, the cash conversion cycle (CCC) is relatively high at 235 days, indicating potential inefficiencies in managing working capital. This prolonged cycle could pose challenges in liquidity management, especially in times of unpredictable cash flows.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vimta Labs reflects a sound financial position, with total assets amounting to ₹518 Cr and total liabilities at ₹467 Cr, resulting in a low total debt-to-equity ratio of 0.06. This indicates a conservative approach to leverage, minimizing financial risk. Reserves have increased from ₹276 Cr in FY 2023 to ₹374 Cr in FY 2025, showcasing the company’s ability to retain earnings for reinvestment. The price-to-book value ratio stands at 3.08x, which is slightly higher than typical sector norms, possibly indicating a premium valuation. Furthermore, the current ratio of 2.91x suggests strong short-term financial health, enabling the company to cover its current liabilities comfortably. The interest coverage ratio further reinforces this strength, allowing Vimta to navigate potential downturns without significant stress.
Shareholding Pattern and Investor Confidence
Vimta Labs’ shareholding structure reveals a diversified ownership model, with promoters holding 35.99% of the company, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 4.33% and 0.87%, respectively. The public holds a substantial 58.80%, reflecting robust retail investor interest. Notably, the number of shareholders has surged from 18,916 in Dec 2022 to 55,933 by Sep 2025, indicating growing investor confidence. Promoter shareholding has seen a gradual decline, down from 37.26% in Dec 2022, which could raise concerns regarding promoter commitment. However, the increasing public shareholding suggests a positive perception of the company’s future prospects. The stability and growth in shareholder numbers may provide Vimta with an expanded base for capital raising and strategic initiatives.
Outlook, Risks, and Final Insight
Vimta Labs is positioned for growth, driven by a solid revenue trajectory and strong profitability metrics. However, the company faces risks associated with its high cash conversion cycle and fluctuating quarterly revenues, which could impact liquidity and operational efficiency. Additionally, the sector’s inherent volatility, influenced by regulatory changes and market dynamics, poses a challenge. While the financial health, marked by low debt levels and robust interest coverage, supports Vimta’s operations, the reliance on project-based revenues could lead to unpredictable cash flows. For investors, the outlook remains cautiously optimistic; should Vimta manage its working capital more efficiently and sustain its revenue growth, it could enhance shareholder value significantly. Conversely, any adverse market conditions or operational inefficiencies may dampen this potential, necessitating close monitoring of future performance indicators.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 77.3 Cr. | 111 | 237/95.0 | 46.6 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,307 Cr. | 515 | 903/372 | 30.9 | 93.5 | 0.19 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,307.00 Cr | 313.00 | 38.75 | 64.35 | 0.10% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 76 | 81 | 82 | 64 | 73 | 73 | 75 | 85 | 90 | 94 | 98 | 102 |
| Expenses | 54 | 55 | 57 | 58 | 48 | 50 | 47 | 49 | 55 | 57 | 61 | 64 | 68 |
| Operating Profit | 25 | 21 | 24 | 24 | 17 | 23 | 26 | 26 | 30 | 33 | 33 | 34 | 34 |
| OPM % | 32% | 27% | 29% | 29% | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% | 34% |
| Other Income | 1 | 1 | 1 | 1 | 0 | -1 | -1 | -1 | -1 | 5 | 2 | 2 | 3 |
| Interest | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 | 10 |
| Profit before tax | 18 | 14 | 16 | 16 | 8 | 13 | 16 | 17 | 20 | 28 | 25 | 25 | 26 |
| Tax % | 26% | 27% | 23% | 25% | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% | 24% |
| Net Profit | 13 | 10 | 12 | 12 | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 | 20 |
| EPS in Rs | 2.95 | 2.25 | 2.77 | 2.63 | 1.34 | 2.14 | 2.79 | 2.77 | 3.44 | 4.84 | 4.12 | 4.24 | 4.47 |
Last Updated: December 28, 2025, 2:33 pm
Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 102.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Jun 2025) to 102.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Sep 2025, the value is 68.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.00 Cr. (Jun 2025) to 68.00 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 34.00 Cr..
- For OPM %, as of Sep 2025, the value is 34.00%. The value appears to be declining and may need further review. It has decreased from 35.00% (Jun 2025) to 34.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Jun 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 10.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Jun 2025) to 26.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Jun 2025) to 24.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.47. The value appears strong and on an upward trend. It has increased from 4.24 (Jun 2025) to 4.47, marking an increase of 0.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 289 | 344 | 384 |
| Expenses | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 195 | 222 | 250 |
| Operating Profit | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 94 | 122 | 134 |
| OPM % | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 33% | 35% | 35% |
| Other Income | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | -4 | 5 | 11 |
| Interest | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 | 2 | 2 |
| Depreciation | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 33 | 35 | 39 |
| Profit before tax | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 55 | 90 | 104 |
| Tax % | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% | 25% | |
| Net Profit | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 41 | 67 | 79 |
| EPS in Rs | 3.00 | 1.14 | 1.45 | 2.40 | 3.72 | 5.73 | 1.57 | 4.81 | 9.29 | 10.68 | 9.26 | 15.13 | 17.67 |
| Dividend Payout % | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | 83.33% | 45.45% | 56.25% | -72.00% | 200.00% | 95.24% | 14.63% | -12.77% | 63.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | 63.33% | -37.88% | 10.80% | -128.25% | 272.00% | -104.76% | -80.60% | -27.40% | 76.18% |
Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 58% |
| 3 Years: | 17% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 72% |
| 3 Years: | 65% |
| 1 Year: | 146% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:12 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 |
| Reserves | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 310 | 374 | 407 |
| Borrowings | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | 9 | 7 |
| Other Liabilities | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 61 | 79 | 95 |
| Total Liabilities | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
| Fixed Assets | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 166 | 230 | 240 |
| CWIP | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 59 | 38 | 55 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 0 | 0 | 0 |
| Other Assets | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 170 | 198 | 224 |
| Total Assets | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 394 | 467 | 518 |
Below is a detailed analysis of the balance sheet data for Vimta Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 374.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 9.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 95.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 518.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 230.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 38.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 17.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 224.00 Cr., marking an increase of 26.00 Cr..
- For Total Assets, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 467.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 51.00 Cr..
Notably, the Reserves (407.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 19.00 | 13.00 | -7.00 | -17.00 | 5.00 | 32.00 | -2.00 | 23.00 | 61.00 | 79.00 | 75.00 | 113.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 110 | 113 |
| Inventory Days | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 154 | 195 | 260 | 210 |
| Days Payable | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 108 | 124 | 87 | 88 |
| Cash Conversion Cycle | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 147 | 164 | 283 | 235 |
| Working Capital Days | 65 | 109 | 99 | 22 | 62 | 78 | 64 | 89 | 87 | 78 | 98 | 96 |
| ROCE % | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 20% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 330,152 | 0.1 | 14.99 | 330,152 | 2025-04-22 17:25:16 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 78 | 0.04 | 0 | 78 | 2025-04-22 17:25:16 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 18.51 | 21.77 | 18.70 | 9.68 | 3.10 |
| Diluted EPS (Rs.) | 18.24 | 21.35 | 18.32 | 9.68 | 3.10 |
| Cash EPS (Rs.) | 33.92 | 35.65 | 29.24 | 20.12 | 12.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Revenue From Operations / Share (Rs.) | 143.55 | 143.78 | 125.86 | 95.29 | 81.73 |
| PBDIT / Share (Rs.) | 40.96 | 44.44 | 36.97 | 24.33 | 14.91 |
| PBIT / Share (Rs.) | 25.53 | 30.57 | 26.42 | 13.89 | 5.44 |
| PBT / Share (Rs.) | 24.57 | 29.37 | 25.19 | 12.91 | 3.74 |
| Net Profit / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| NP After MI And SOA / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| PBDIT Margin (%) | 28.52 | 30.91 | 29.37 | 25.52 | 18.24 |
| PBIT Margin (%) | 17.78 | 21.25 | 20.98 | 14.57 | 6.65 |
| PBT Margin (%) | 17.11 | 20.42 | 20.01 | 13.54 | 4.57 |
| Net Profit Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| NP After MI And SOA Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| Return on Networth / Equity (%) | 12.82 | 17.09 | 17.66 | 11.01 | 3.95 |
| Return on Capital Employeed (%) | 16.36 | 22.17 | 22.51 | 13.92 | 6.39 |
| Return On Assets (%) | 10.25 | 13.29 | 13.45 | 7.80 | 2.78 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.05 | 0.07 | 0.03 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.08 | 0.11 | 0.13 |
| Asset Turnover Ratio (%) | 0.83 | 0.95 | 0.95 | 0.81 | 0.00 |
| Current Ratio (X) | 2.91 | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio (X) | 2.46 | 2.46 | 2.24 | 1.78 | 1.37 |
| Dividend Payout Ratio (NP) (%) | 10.79 | 9.17 | 10.69 | 0.00 | 64.60 |
| Dividend Payout Ratio (CP) (%) | 5.88 | 5.60 | 6.83 | 0.00 | 15.91 |
| Earning Retention Ratio (%) | 89.21 | 90.83 | 89.31 | 0.00 | 35.40 |
| Cash Earning Retention Ratio (%) | 94.12 | 94.40 | 93.17 | 0.00 | 84.09 |
| Interest Coverage Ratio (X) | 42.79 | 37.19 | 54.56 | 24.81 | 8.76 |
| Interest Coverage Ratio (Post Tax) (X) | 20.33 | 19.21 | 29.41 | 10.87 | 2.82 |
| Enterprise Value (Cr.) | 979.08 | 670.65 | 704.61 | 372.30 | 147.42 |
| EV / Net Operating Revenue (X) | 3.08 | 2.11 | 2.53 | 1.77 | 0.81 |
| EV / EBITDA (X) | 10.78 | 6.82 | 8.62 | 6.92 | 4.47 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| Retention Ratios (%) | 89.20 | 90.82 | 89.30 | 0.00 | 35.39 |
| Price / BV (X) | 3.08 | 2.47 | 2.98 | 1.83 | 0.75 |
| Price / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| EarningsYield | 0.04 | 0.06 | 0.05 | 0.06 | 0.05 |
After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
- For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
- For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
- For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
- For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
- For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
- For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
- For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
- For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
- For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
- For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
- For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
- For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
- Net Profit Margin: 12.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.36% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.82% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 20.33
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.9 (Industry average Stock P/E: 38.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot Nos. 141/2 & 142, Hyderabad Telangana 500051 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sivalinga Prasad Vasireddi | Executive Chairman |
| Ms. Harita Vasireddi | Managing Director |
| Mr. Harriman Vungal | Executive Director - Operations |
| Mr. Satya Sreenivas Neerukonda | Executive Director |
| Dr. Yadagiri R Pendri | Independent Director |
| Ms. Prameela Rani Yalamanchili | Independent Director |
| Mr. Sanjay Dave | Independent Director |
| Mr. Purnachandra Rao Gutta | Independent Director |
FAQ
What is the intrinsic value of Vimta Labs Ltd?
Vimta Labs Ltd's intrinsic value (as of 24 January 2026) is ₹510.90 which is 0.80% lower the current market price of ₹515.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,307 Cr. market cap, FY2025-2026 high/low of ₹903/372, reserves of ₹407 Cr, and liabilities of ₹518 Cr.
What is the Market Cap of Vimta Labs Ltd?
The Market Cap of Vimta Labs Ltd is 2,307 Cr..
What is the current Stock Price of Vimta Labs Ltd as on 24 January 2026?
The current stock price of Vimta Labs Ltd as on 24 January 2026 is ₹515.
What is the High / Low of Vimta Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vimta Labs Ltd stocks is ₹903/372.
What is the Stock P/E of Vimta Labs Ltd?
The Stock P/E of Vimta Labs Ltd is 30.9.
What is the Book Value of Vimta Labs Ltd?
The Book Value of Vimta Labs Ltd is 93.5.
What is the Dividend Yield of Vimta Labs Ltd?
The Dividend Yield of Vimta Labs Ltd is 0.19 %.
What is the ROCE of Vimta Labs Ltd?
The ROCE of Vimta Labs Ltd is 25.2 %.
What is the ROE of Vimta Labs Ltd?
The ROE of Vimta Labs Ltd is 19.4 %.
What is the Face Value of Vimta Labs Ltd?
The Face Value of Vimta Labs Ltd is 2.00.